Syntara Ltd (ASX:SNT) CEO Gary Phillips joins Proactive’s Jonathan Jackson to share insights on the company's expansion of its lead drug, SNT-5505, into new medical indications, including a promising Phase 2 study targeting myelodysplastic syndrome (MDS). Phillips highlighted the significance of SNT-5505 in addressing MDS, a complex condition, underscoring the drug's potential impact on patient care. The company is collaborating with several partners in a strategic move that fosters local partnerships to advance the research. From a commercial standpoint, this development represents a pivotal advancement for Syntara, as it embarks on its fourth concurrent Phase 2 study, balancing the demands of cash flow and timelines effectively. Looking ahead, Phillips hinted at an ambitious roadmap for Syntara, signalling a period of intense activity and innovation as the company continues to explore the therapeutic potential of SNT-5505 and its impact on treating challenging medical conditions.
Syntara to start Phase 2 study targeting MDS
